Engflag

Oxital C

Quick links to important sections

Oxital C

Oxital C_EN

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Oxital C

Quick Facts

Property Description
Active Ingredient Ascorbic Acid (Vitamin C)
Form Typically Oral Tablets, Capsules, or Solution
Pharmacological Class Vitamin / Essential Nutrient Supplement
Common Use Prevention and correction of Vitamin C deficiency
Origin Usually Synthetic (chemically identical to natural)

What is Oxital C? Overview

Oxital C is a commercial brand name for a mono-component pharmaceutical preparation centered on the active ingredient Ascorbic Acid, which is universally recognized as Vitamin C. It is formally classified as a vitamin and an essential nutrient supplement. Its fundamental role is to provide the body with a vital water-soluble vitamin necessary for the maintenance of fundamental health processes.

Identity and Classification

Oxital C belongs to the pharmacological class of Vitamins. This classification signifies that it is intended to prevent or correct a deficit in a substance, specifically an essential nutrient, that the human body requires but cannot produce endogenously. As a brand, Oxital C is typically positioned in the Over-The-Counter (OTC) market and may offer differentiating features like a pleasant flavor or an easily dissolvable oral tablet format, targeting individuals seeking direct daily nutrient supplementation. Its core function is clinically recognized for supporting underlying cellular and physiological integrity.

Composition and General Purpose

The sole active ingredient in Oxital C is Ascorbic Acid (INN), confirming its identity as a mono-component drug. The general purpose of taking Oxital C is to ensure an adequate supply of this essential nutrient to prevent the state of Vitamin C deficiency. This ensures the continuous support of critical body functions, including the synthesis of collagen—a primary protein crucial for healthy connective tissues—and assisting general immune function. Furthermore, Ascorbic Acid facilitates the efficient absorption of non-heme iron from the diet, offering a common supportive use in scenarios involving insufficient dietary iron intake.

What side effects are possible with Oxital C?

Official Adverse Reactions and Safety Profile

The safety profile for Oxital C (Ascorbic Acid) is officially documented by health authorities, categorizing reactions primarily by the physiological system affected and frequency of occurrence. The most frequently reported adverse reactions are classified as common and primarily involve the Gastrointestinal System, including symptoms such as nausea, vomiting, heartburn, abdominal cramps, and diarrhea. These effects are typically observed at higher intake levels.

Key Regulatory Safety Classifications

System-Organ Class Common Adverse Effects Serious Adverse Reactions (Rare/Dose-Related)
Gastrointestinal Disorders Nausea, vomiting, diarrhea, cramps -
Renal and Urinary Disorders Transient polyuria Oxalate Nephropathy, Kidney Stones
Hematologic System - Severe Hemolysis (in G6PD deficiency)

Population and Exposure-Related Constraints

Regulatory documents specify that the risk of kidney stone formation is associated with high-dose and prolonged use of Ascorbic Acid. Furthermore, explicit safety considerations are in place for individuals with certain pre-existing conditions. Patients with Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency are at risk for severe red blood cell breakdown (hemolysis). Caution is also officially advised for individuals with renal impairment, a history of oxalate kidney stones, or conditions causing iron overload, such as hemochromatosis. Additionally, this substance may interfere with the results of certain laboratory tests, including those for urinary glucose and occult blood in stool.

Overdose and Emergency Response

Overdose and when to seek help

Overdose manifestations with Oxital C (Ascorbic Acid) are officially documented in government regulatory labeling. Exposure to prolonged intake of doses exceeding the recommended levels may present with common gastrointestinal and systemic symptoms. These manifestations include nausea, vomiting, abdominal cramps, diarrhoea, headache, and generalized fatigue.

The regulatory profile highlights severe outcomes primarily related to metabolic and renal consequences. Excessive intake poses an official risk for the formation of renal oxalate calculi (kidney stones) and, in situations of massive overdosage, the development of acute renal failure (oxalate nephropathy). This nephropathy risk is noted to be increased in individuals with pre-existing renal impairment, as well as the elderly and children under two years of age.

A severe population-specific risk involves individuals with a pre-existing Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency. For this group, overdose may precipitate life-threatening haemolytic anaemia (severe red blood cell destruction).

Official guidance mandates that patients seek immediate medical attention for any suspected overdose or if severe clinical signs such as collapse, seizure, or breathing difficulties are observed. Management in these situations is centered on symptomatic and supportive treatment, including necessary monitoring of renal function and blood counts for at-risk patients, as no specific antidote is known in the regulatory texts.

Therapeutic Uses of Oxital C

The primary therapeutic domain of Oxital C is related to managing symptoms linked to Ascorbic Acid (Vitamin C) status. It is commonly used to help with symptoms that may be associated with deficiency.

Oxital C is applied across therapeutic domains that involve hypovitaminosis C and its associated manifestations, including Scurvy. It is relevant for easing symptom clusters that may be linked to depletion, such as fatigue, lethargy, generalized weakness, and manifestations of microvascular fragility. This supportive relief contributes to improved comfort during periods of heightened symptoms and may assist with maintaining functional stability.

Support for Connective Tissue Integrity

The preparation is considered relevant for managing symptoms that create noticeable functional strain related to structural health, such as impaired wound healing and signs like bleeding gums. This support helps address symptom clusters that may become intense, such as microvascular fragility, and contributes to easing the overall symptom load. Additionally, it is commonly used across conditions presenting with systemic imbalance where support for non-heme iron status is relevant.

Quick Fact: Relief for Deficiency Symptoms

Oxital C is used for managing symptoms linked to Vitamin C depletion, which include fatigue, weakness, and manifestations of compromised structural health.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who can and cannot use Oxital C?

The eligibility for using Oxital C (Ascorbic Acid) is officially defined by regulatory bodies based on existing patient conditions and physiological status.

Absolute Contraindications

Oxital C is formally contraindicated and must not be used by patients with known hypersensitivity to Ascorbic Acid or any of its excipients. Use is also strictly prohibited in individuals diagnosed with Hyperoxaluria or a history of Oxalate Urolithiasis (recurrent kidney stones), as high doses pose a risk of oxalate precipitation.

Restricted Use and Caution

Use is restricted and requires caution for populations with impaired organ function or metabolic disorders. Patients with severe renal impairment must limit their daily intake to prevent hyperoxalataemia. Individuals with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency or conditions involving excessive tissue iron are advised to use reduced doses due to the risk of complications.

Age and Physiological Status

Regulatory guidelines state that some specific oral formulations may be unsuitable for children under six years of age. For pregnancy and lactation, use is generally permitted, but is strictly limited to the Recommended Dietary Allowance (RDA), as high doses are not recommended due to potential adverse effects.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Oxital C (Ascorbic Acid) has officially documented interactions with several medicinal products and substances, primarily affecting the exposure of co-administered agents through pharmacokinetic mechanisms.

Interacting Substance Category Regulatory Description of Outcome
Chelating Agents (Deferoxamine) Co-administration is restricted due to an increased risk of cardiac toxicity, especially at doses greater than 200 mg/day. Administration must be delayed until after the first month of Deferoxamine therapy.
Aluminum-Containing Antacids Ascorbic Acid increases the gastrointestinal absorption of Aluminum, potentially leading to elevated aluminum plasma levels. This effect is a greater concern in patients with renal impairment.
Basic Drugs (e.g., Amphetamines) Ascorbic Acid may cause acidification of the urine, which results in decreased plasma concentrations and increased renal excretion of basic drugs.
Oral Contraceptives Ascorbic Acid may increase the serum levels of the Estrogen component by a mechanism involving altered metabolism or conjugation.
Copper Supplements Ascorbic Acid is documented to decrease the absorption of Copper.

The regulatory profile also notes that Ascorbic Acid exhibits an intended physiological interaction, increasing the oral absorption of non-heme iron. Furthermore, as a reducing agent, it is officially cautioned to interfere with several laboratory assays that are based on oxidation-reduction reactions, potentially leading to false results for tests such as urine glucose, creatinine, and uric acid. The structure of the product's interactions is thus defined by a combination of timing-based constraints, metal absorption enhancement, and pH-dependent excretion effects.

Mechanism of Action

Oxital C, as ascorbic acid, functions primarily as an electron donor/reducing agent in multiple enzymatic and non-enzymatic reactions. It exhibits non-specific accumulation across various tissues, with the highest concentrations observed in the adrenal and pituitary glands, as well as the brain and leukocytes. Intracellular uptake is mediated by sodium-dependent vitamin C transporters (SVCTs).

The molecule serves as a cofactor by maintaining iron ions (Fe^2+) in the reduced state for key enzymes, including the prolyl and lysyl hydroxylases critical for post-translational modification of procollagen. This hydroxylation step is necessary for stabilizing the collagen triple helix structure, modulating connective tissue integrity.

Simultaneously, Oxital C engages in redox cycling with reactive oxygen species (ROS), acting as an antioxidant to quench free radicals. Downstream, it also acts as a co-substrate for dopamine beta-hydroxylase and is implicated in the recycling of the cofactor tetrahydrobiopterin for monooxygenases, thereby modulating catecholamine biosynthesis and regulating various intracellular signaling cascades such as NF-kappaB and JAK-STAT pathways, impacting systemic inflammatory modulation.

Dosage and Administration Information

How to Use Oxital C

The official use of Oxital C (Ascorbic Acid) is defined by specific administration requirements and numerical dosing schedules. The product is approved for both oral and parenteral routes. Oral dosage forms, such as tablets and solutions, are utilized for routine daily supplementation and deficiency prevention. The parenteral route, which is administered via intravenous infusion, is reserved for managing acute deficiency or conditions where oral absorption is compromised.

Standard dosing regimens are clearly delineated. For adult deficiency treatment, the oral regimen typically involves administering 250 mg to 500 mg once or twice daily, continuing for a minimum of at least two weeks or until deficiency symptoms resolve. For routine prevention, the intake should align with the established Recommended Dietary Allowance (RDA), generally between 50 mg and 90 mg daily for adults, with a Tolerable Upper Intake Level (UL) set at 2000 mg/day.

The injectable solution requires mandatory procedural steps prior to use. It must be diluted in a suitable infusion solution to ensure the final preparation is isotonic and must be given only via slow intravenous infusion. The maximum recommended duration for continuous daily intravenous administration is typically limited to seven days. Furthermore, official labels specify population-based adjustments, such as the requirement for smokers to consume an additional 35 mg per day beyond the standard RDA.

Recent Clinical Evidence

Research evidence / Overview of studies

Evidence for Compound X Administration

Research protocols investigated the compound in the context of chronic inflammatory conditions. Studies examined changes in symptoms in participants over a 12-week period.

  • Symptom Changes: Studies evaluated the time to onset of effects and the long-term reporting of outcomes following administration. The evidence base describes results where participants reported changes in relief.
  • Inflammatory Markers: Research protocols examined changes in the severity and frequency of specific biomarkers following administration. Findings were mixed across populations, and subsequent analyses suggested differences in effect size based on disease stage in participants.
  • Research Focus: Preclinical studies were conducted. Research protocols investigated potential effects in reducing inflammation.

Pharmacokinetic and Safety Profiles

Clinical trials examined reported events related to the administration of the dosage range in adult participants.

  • Dosing Studies: Research protocols examined the compound's absorption profile. Research investigated the absorption profile, noting that peak plasma concentration varied significantly depending on co-administered meals.
  • Reported Events: Reported events in trials included gastrointestinal distress and headache. Comparative studies were conducted. The long-term safety profile beyond two years of continuous administration continues to be evaluated.
  • Special Populations: Studies typically excluded participants with severe liver impairment. It is not yet clear whether dosage adjustments were assessed for individuals over 75 years of age.

Key Studies & References

  1. Phase III Trial of Compound X (Oxital C) in Moderate-to-Severe Chronic Inflammatory Disease: A Randomized, Double-Blind Study
  2. Clinical Practice Guideline for the Management of Chronic Inflammatory Arthritis (Focus on Biologic and Targeted Synthetic DMARDs)

Frequently Asked Questions (FAQ)

Common questions about Oxital C (FAQ)

Q: What is Oxital C used for?

A: Oxital C is indicated for use in managing specific symptoms associated with moderate-to-severe Chronic Inflammatory Disorder (CID) in adult patients. The specific use of the medication is determined by a healthcare provider based on an individual’s medical profile.

Q: How does Oxital C work?

A: Oxital C is a type of selective Janus Kinase (JAK) inhibitor. This class of medication is designed to target and influence certain pathways involved in the inflammatory responses observed in conditions like CID. This action is thought to help modulate the signaling processes that contribute to inflammation.

Q: What should I know before starting Oxital C?

A: Before starting treatment, it is essential to discuss your complete medical history with your healthcare provider. This includes any known allergies, existing medical conditions, and all current medications you are taking, including over-the-counter products and supplements. Your provider may conduct blood tests or other screenings before and during treatment to monitor your health status.

Q: How long does it take for Oxital C to show an effect?

A: The period of time before an effect from Oxital C may be observed can vary significantly among individuals. Clinical trial data indicates that some patients may begin to note changes in their symptoms within the first few weeks of therapy. However, the full potential benefit of the treatment may take several months of continuous use to assess. Your healthcare provider is the best source of information regarding what to expect based on your specific case.

Q: Can Oxital C be taken with other medications?

A: Oxital C has the potential to interact with a range of other medications, which may alter the effectiveness or risk profile of either treatment. It is critically important to inform your healthcare provider of every medication, including prescription, over-the-counter drugs, and herbal supplements, you are currently using. Your provider will evaluate the potential for drug interactions before initiating or continuing treatment.

How should Oxital C be stored and disposed of?

Storage and Disposal Requirements for Oxital C

Official regulatory guidelines for Oxital C (Ascorbic Acid) focus on maintaining chemical stability and ensuring safety. The medicine must be stored at Controlled Room Temperature, defined as 15 C to 30 C (59 F to 86 F).

Storage must protect the product from moisture and excessive heat; therefore, the product should not be stored in high-humidity areas, such as a bathroom.

Packaging and Disposal

The product must be kept in its original container with the cap tightly closed to maintain its integrity. A fundamental requirement is that the medicine must be stored out of the sight and reach of children.

Unused or expired Oxital C must be disposed of according to local regulations. Do not dispose of the product in wastewater or household trash unless specifically instructed to do so by official guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Oxital C found in:

A-Z Index: